No share repurchases have been completed to date in 2025. As of August 5, 2025, Pfizer’s (PFE) remaining share repurchase authorization is $3.3B. Current financial guidance does not anticipate any share repurchases in 2025. The company expects to continue to de-lever in a prudent manner in order to maintain a balanced capital allocation strategy. This includes maintaining the flexibility to deploy capital towards potential value-creating business development transactions and the potential to return capital to shareholders through share repurchases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer reports Q2 adjusted EPS 78c, consensus 57c
- Pfizer raises FY25 adjusted EPS view to $2.90-$3.10 from $2.80-$3.00
- Pfizer’s Long-Term Study on Ritlecitinib Offers Hope for Alopecia Areata Treatment
- Pfizer’s Phase 1 Study on Drug Interactions: Key Insights for Investors
- Pfizer’s PF-07275315 Study: A Step Forward in Drug Development